Insider Buying: Senestech, Inc. (SNES) Director Purchases $32,100.00 in Stock

Senestech, Inc. (NASDAQ:SNES) Director Julia Ann Williams purchased 10,000 shares of the business’s stock in a transaction on Wednesday, July 26th. The stock was purchased at an average cost of $3.21 per share, for a total transaction of $32,100.00. Following the completion of the acquisition, the director now directly owns 11,950 shares of the company’s stock, valued at approximately $38,359.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Senestech, Inc. (NASDAQ SNES) opened at 3.2299 on Friday. The firm has a 50-day moving average of $5.18 and a 200 day moving average of $7.11. Senestech, Inc. has a 12-month low of $3.14 and a 12-month high of $10.69. The stock’s market capitalization is $32.99 million.

Senestech (NASDAQ:SNES) last issued its earnings results on Thursday, May 11th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.13. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.24 million. On average, analysts predict that Senestech, Inc. will post ($1.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by [[site]] and is owned by of [[site]]. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at [[permalink]].

Several research firms have issued reports on SNES. Roth Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Senestech in a report on Friday, March 31st. Zacks Investment Research lowered shares of Senestech from a “hold” rating to a “sell” rating in a report on Thursday, June 1st.

About Senestech

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.